Anlotinib, a novel multi-targeting tyrosine kinase inhibitor (VEGFR, FGFR, PDGFR, and c-Kit), is approved by the National Medical Products Administration (NMPA) in China for the treatment of locally advanced or metastatic non-small-cell lung cancer (NSCLC) patients who develop tumor progression or recurrence after ≥2 lines of systemic chemotherapy (Syed, 2018). The gene discussed is PDGFRB; the disease is non-small cell lung carcinoma.